Objective: To test the anti-tumor effect of breast cancer fusion protein vaccine HSP 65-HER2 combined with CpG684. Methods:Mice were subcutaneously injected with HSP65-HER2 plus GpG684, PBS, CpG684 for three times in a 7-day interval, and then inoculated intraperitoneally (I. P) with 7. 5 × 10 HER2 positive B16 melanoma transfected with pcDNA3-GFP-HER2 plasmid. The mice were monitored for 70 days after tumor inoculation for recording their survivals . Results:On the day 70 after tumor inoculation, 80% of mice in HSP65-HER2 plus CpG684 groups were still alive , while only 10% of mice in CpG684 group were alive and all mice in PBS group had been dead on day 36 after tumor inoculation. The results showed that compared with PBS and CpG 684 groups, the survival of mice immunized with HSP65-HER2 and CpG684 was significantly prolonged (P <0. 01). Conclusion:The HSP65-HER2 plus CpG684 showed vigorous anti-tumor effect in vivo that will be very helpful for the further clinical research and use .%目的:检测人乳腺癌融合蛋白疫苗HSP65-HER2联用CpG684的抗肿瘤效果.方法:C57BL/6小鼠分别皮下注射PBS,CpG684,HSP65-HER2和CpG684混合物,一周一次,共三次,随后给小鼠腹腔接种7.5×104个转染了pcDNA3-GFP-HER2质粒的B16肿瘤细胞(HER2+B16),监测各组小鼠的生存期至接种肿瘤后70天.结果:免疫了HSP65-HER2和CpG684的小鼠在接种肿瘤后70天时,仍有80%存活,而GpG684组的小鼠仅有10%存活,PBS组小鼠在接种肿瘤后36天后全部死亡.与PBS和CpG684对照组相比,免疫了HSP65-HER2和CpG684的小鼠的生存期显著延长(P＜0.01).结论:HSP65-HER2联用CpG684在体内发挥了强大的抗肿瘤活性,为进一步的临床研究和应用奠定了基础.
展开▼
